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Summary
The tumour suppressor p53 is commonly detected in tissues of companion animals
by means of antibodies raised against the human orthologue. The following three-
step procedure was devised to test the suitability of such antibodies for
immunohistochemistry on canine tissues. (1) Western blot and immunohistochemical
analyses on bacterially expressed recombinant canine protein to assess human-to-
canine cross-reactivity. (2) Immunohistochemistry of cultured, UVB-irradiated canine
keratinocytes to evaluate suitability for detection of endogenous p53. (3)
Immunohistochemistry on tissue arrays to further substantiate suitability of the
antibodies on a panel of normal and neoplastic human and canine tissues. Five of six
antibodies cross-reacted with recombinant canine p53. Three of these (PAb122,
PAb240, CM-1) also immunohistochemically recognized stabilized wild type p53 in
cell cultures and elicited a consistent, characteristic labelling pattern in a subset of
tumours. However, two alternative batches of polyclonal antibody CM-1 failed to
detect p53 in cell cultures, while showing a characteristic labelling pattern of a
completely different subset of tumours and unspecific labelling of normal tissues.
The test system described is well suited to the selection of antibodies for
immunohistochemical p53 detection. The results emphasize the need to include
appropriate controls, especially for polyclonal antibodies.
Introduction
The tumour suppressor p53 is of pivotal importance for the control of cell cycle arrest,
DNA repair, and apoptosis following DNA damage (Chipuk and Green, 2006).
Mutations of the p53 gene are frequent in human cancer (Vogelstein et al., 2000).
5The mutated protein displays altered function and has a prolonged half-life, which
leads to its intranuclear accumulation and renders it detectable by
immunohistochemistry. This technique is widely used to screen for mutated p53 due
to its simplicity, relatively high throughput and low cost as compared with mutational
analysis, which is in turn more reliable and more informative (Soussi and Beroud,
2001). Numerous human studies have shown that p53 immunoreactivity is correlated
with poor prognosis in several different types of tumour, while other studies have
failed to confirm such correlation (Kirsch and Kastan, 1998; Peller, 1998). Analysis of
the data available from the literature on human p53 indicates lack of standardization
as a major source of discrepancies between different laboratories (Soussi and
Beroud, 2001; Munro et al., 2005). Immunohistochemical assessment of the p53
status has been performed for several different types of canine tumours to determine
its importance in tumorigenesis (Table 1), its possible correlation with parameters
associated with biological behaviour, or its prognostic significance (Sagartz et al.,
1996; Wolf et al., 1997; Ginn et al., 2000; Jaffe et al., 2000; Loukopoulos et al.,
2003).
Most commercially available antibodies are raised against human- or mouse-specific
immunogens. Use of such antibodies on canine tissues is associated with potential
problems, including lack of interspecies cross-reactivity due to epitope sequence
differences or insufficient specificity due to cross-reaction with unrelated antigens. A
number of different antibodies have been used for the immunohistochemical
detection of p53 in canine tissues (reviewed in Table 1). Most studies rely on CM-1, a
polyclonal antibody raised against full-length recombinant human p53. Clone
PAb240, is the second most commonly used antibody. In addition, the use of at least
11 further antibodies has been reported, mainly in single studies and with small
numbers of samples. In the publications listed in Table 1, positive controls consisted
mainly of human positive tissues (seven studies), of canine positive tumour tissues
(three studies) or both (three studies). Paraffin wax-embedded canine cell cultures
transformed with SV40 large T antigen to enforce p53 stabilization were used in four
studies; in reports of 10 studies, positive controls were not mentioned. Negative
controls included either omission of the primary antibody (five studies) or use of non-
immune serum instead of the primary antibody (nine studies), variably combined with
the use of internal tissue controls (10 studies) or of normal tissues (five studies).
Reports of 11 studies made no mention of negative controls.
6The purpose of the present study was to devise a system for selecting
commercially available antibodies for immunohistochemical detection of canine p53.
Table 1: Antibodies against p53 and use in immunohistochemistry of canine tumours
Antibody Immunogen/
epitope*
Species of
immunogen
Homology,
human-
canine†
References to canine tumours
BP53-12 19-25 human 5,6/7 Haga et al., 2001
DO-1 20-25 human 4,5/6 Johnston et al., 1996; Kawaura et al., 2001; Roels et al., 2001
DO-7 20-25 human 4,5/6 Albaric et al., 2001
DO-12 256-270 human 14,15/15 no reference
DO-13 26-35 human 8,10/10 no reference
PAb122 370-378 human 8,9/9 Haga et al., 2001
PAb240 213-217 human 5/5 Albaric et al., 2001; Johnston et al., 1996; Lee et al., 2004;
Roels et al., 2001; Teifke and Lohr, 1996; Teifke et al., 1998
PAb246 88-109 mouse 17,17/22 Inoue and Wada, 2000
PAb421 371-380 human 9,10/10 Lee et al., 2004
PAb1801 46-55 human 2,4/10 Inoue and Shiramizu, 1999; Johnston et al., 1996
CM-1 full length human 318,341/394 Albaric et al., 2001; Gamblin et al., 1997; Ginn et al., 2000; Jaffe
et al., 2000; Loukopoulos et al., 2003; McEntee and Brenneman,
1999; Murakami et al., 2000; Nieto et al., 2003; Ozaki et al.,
2002; Pena et al., 2003; Roels et al., 2001; Rungsipipat et al.,
1999; Sagartz et al., 1996; Schafer et al., 1998; Sokolowska et
al., 2005; Sueiro et al., 2004; Wakui et al., 2001; Wolf et al., 1997
FL-393 full length human 318,341/394 Inoue and Wada, 2000
NCD NCD NCD Vitellozzi et al., 1998; Stoica et al., 2004
* Amino-acid position of human p53.
† A,B/C; A, number of identical amino acids; B, number of similar amino acids; C, total number of amino acids.
References in bold print indicate studies in which several antibodies were used.
NCD, not clearly defined.
7Materials and Methods
Primary Antibodies for Immunohistochemistry
Antibodies against p53. Based on the canine p53 protein reference sequence
available from Genbank (NP_001003210) and on the sequence of our own clone, we
identified commercially available antibodies raised against peptides displaying the
highest sequence homology possible with the canine orthologue. A further selection
criterion was previous successful use according to the literature (Table 1). The
following antibodies against p53 were included: two rabbit polyclonal antibodies (both
CM-1; Novocastra, Newcastle upon Tyne, UK, Lot No. 300507 and 300509; Signet
Laboratories, Dedham, MA, USA, Lot No. 05DC00654 and 05LC02510), five mouse
monoclonal antibodies (clone DO-7, Dako Cytomation, Glostrup, Denmark; clone
DO-12, Serotec, Oxford, UK; clone DO-13, Serotec; clone PAb122, Monosan, Uden,
Netherlands; clone PAb240, Dako).
Antibodies against other molecules. A rabbit polyclonal antibody specific for cleaved
caspase-3 (AF835, R&D Systems, Abingdon, UK) was used. This antibody is
directed against an epitope adjacent to the human caspase-3 cleavage site, which is
identical with the corresponding canine sequence.
Cloning of p53 and Expression in Escherichia coli
Cloning of the p53 open reading frame (ORF) will be described in detail elsewhere
(Schade et al., to be published). Briefly, total RNA was isolated from Madin Darby
Canine Kidney (MDCK) cells with the RNeasy Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer's instructions. Then 40 U of the Protector RNAse
Inhibitor (Roche, Mannheim, Germany) were added to the extract. Complementary
DNA was synthesized from 1 µg total RNA with an oligo-dT-primer and the first
strand cDNA Synthesis Kit for RT-PCR (AMV) according to the instructions of the
manufacturer (Roche).
The p53 ORF was amplified by the PCR with primers p53CExUp (5'-
atgaattcctgcgatgcaagagccac-3') and p53CExDn (5'-taatgtcgacgaagtcagtctgagtcggg-
3') and with the “Platinum Taq DNA Polymerase High Fidelity” (Invitrogen, Carlsbad,
CA, USA), and cloned by sticky-end ligation into the inducible glutathione S-
transferase (GST)-tagged pGEX-4T2 bacterial expression vector (Invitrogen).
Vectors were transformed into DH5a competent cells (Invitrogen) and individual
8clones sequenced (Microsynth AG, Balgach, Switzerland). A clone containing the
correct p53 sequence was transformed into BL-21 Star E. coli (Invitrogen) for protein
expression. Cultures of bacteria containing the GST-p53 fusion construct and the
empty vector coding for GST alone were grown to an OD600 of 0.5 – 0.8 in LB
medium (Oxoid AG, Pratteln, Switzerland) supplemented with ampicillin. Protein
expression was induced by adding 1mM isopropyl-beta-D-thiogalactopyranoside
(IPTG). The bacteria were harvested after 2.5 h of further growth under the same
conditions and processed either for Western blotting or for paraffin wax embedding.
Western Blots
Bacteria were pelleted by centrifugation of 1-ml cultures. The supernate was
discarded and the pellets were resuspended in 200 µl of 2x sodium dodecyl sulphate
(SDS) buffer containing β-mercaptoethanol 10%. After incubation for 10 min at 95°C,
10 to 20 µl of bacterial lysates were loaded on 8% SDS polyacrylamide gels and
separated by gel electrophoresis (SDS-PAGE). The proteins were transferred to a
nitrocellulose membrane by means of a semi-dry blotting system (Biometra,
Goettingen, Germany). Non-specific antibody binding sites were blocked by
incubation of the membrane for 1 h at room temperature in Tris-buffered saline
containing Tween 20 0.05% (TBST) and with milk powder 4%. After washing for 1x
15 min and 2x 5 min in TBST, the membrane was incubated for 1 h at room
temperature with primary antibodies DO-12, DO-13, PAb122, PAb240 and CM-1
(Novocastra, Lot No. 300507) diluted 1 in 500 in TBST containing BSA 3%. The
secondary antibodies (Goat-anti-mouse-HRP [Geno Technologies, St Louis, MO,
USA] diluted 1 in 10 000 and anti-rabbit-HRP [Jackson ImmunoResearch, Soham,
UK ] diluted 1 in 20 000) were applied for 1 h at room temperature in TBST
containing BSA 3%. The signal was detected by incubating the membrane with Lumi
Glo (KPL, Maryland, USA) following the instructions of the supplier.
Cell Culture and Ultraviolet B (UVB) Irradiation
Normal canine keratinocyte cultures (passage 18) have been described previously
(Kolly et al., 2005). The cells were grown in 5% CO2 at 37°C in Dulbeccos' Modified
Eagles medium supplemented with non-essential amino acids 1%, sodium pyruvate
1%, penicillin/streptomycin 1% and fetal calf serum 15% (all cell culture reagents
from Gibco BRL Life Sciences, Basel, Switzerland).
9To induce apoptosis, the cells were irradiated at a dose of 100 mJ/cm2 UVB
with a DNA crosslinker (ltf Labortechnik, Wasserburg, Germany) with an emission
peak at 312 nm. Four plates were irradiated at different timepoints, each with a single
dose. The first time point was at 24 h after plating, when cells had reached about
50% confluence. The subsequent irradiations followed at 6-h intervals, the final dose
being delivered 42 h after plating. During irradiation, the culture medium was
replaced with phosphate-buffered saline (PBS); thereafter the cells were further
incubated in culture medium. All cultures were harvested simultaneously 48 h after
plating and were further processed together. Cells not exposed to UV irradiation but
washed with PBS served as negative controls. The cells were either grown in 60 mm2
culture dishes for paraffin wax embedding or in 24 well plates containing coverslips
for Giemsa staining.
Giemsa Staining
The cells were rinsed four times with PBS, fixed with methanol for 10 min, and
stained with Giemsa (1 in 10 in distilled water) for 10 min. After a brief treatment with
acetic acid and isopropanol, the coverslips were mounted on glass slides (Erie
Scientific Company, Portsmouth, NH, USA) with Shandon-Mount (Thermo Electron
Corporation, Waltham, MA, USA).
Fluorescence-Activated Cell Sorting (FACS) Analysis
Normal keratinocytes were irradiated with a single dose of UVB (100 mJ/cm2) 24 h
after plating as described above, or left untreated (control). Twenty-four hours later
the cells were rinsed twice with PBS and trypsinized. After centrifugation (2 min at
600g) cell pellets were resuspended in Annexin V binding buffer (10mM
Hepes/NaOH, 140 mM NaCl and 2.5 mM CaCl2) containing ethidium bromide (EtBr)
1 µg/ml and Annexin V FITC 5% (BD Pharmingen, Basel, Switzerland). The samples
were incubated for 15 min at room temperature and subsequently analysed by flow
cytometry (FACSCalibur apparatus with BD CellQuestTM Pro software (BD
Pharmingen, Becton Dickinson).
Fixation and Embedding of Bacteria and Keratinocytes
Bacterial culture (100 ml) was centrifuged at 4000g for 10 min at 4°C. The supernate
was discarded and the pellets were resuspended in 4% neutral buffered
10
formaldehyde and incubated for 24 h at room temperature. Subsequently, the
cultures were centrifuged at 4000g for 10 min at room temperature and the pellets
were resuspended in 1.5 ml of BSA 5% in PBS and transferred into Eppendorf tubes.
After centrifugation at 13 000 rpm at room temperature for 10 min the pellets were
embedded in paraffin wax by the Cytoblock system (Thermo Shandon, Pittsburgh,
PA, USA) and a routine embedding procedure.
Keratinocytes were fixed in 4% neutral buffered formaldehyde for 1 h and then
harvested with a cell scraper. After centrifugation for 5 min at 3000g and two washes
with PBS, the supernate was discarded and the pellets were resuspended in 1.5 ml
of bovine serum albumin 5% in PBS and transferred to Eppendorf tubes. The cells
were then centrifuged at 3000g for 10 min and the resulting pellets were paraffin
wax-embedded by the Cytoblock system (Thermo Shandon, Pittsburgh, PA, USA) as
above.
Tissue Array Construction
Tissue arrays were constructed from archival samples by means of a manual tissue
arrayer (Beecher Instruments, Sun Prairie, WI, USA). They included human tumour
tissues with known immunohistochemical p53 status (one positive and two negative
colon carcinomas; two positive and one negative breast carcinomas) and canine
normal and neoplastic tissues. The canine normal tissues consisted of all major
organs, each derived from three different animals and were free of histopathological
lesions. Samples included stomach, duodenum, jejunum, colon, spleen, tonsil, lymph
node, thymus, liver, kidney, thyroid gland, skeletal muscle, brain, spinal cord, ovary,
uterus, vagina, mammary gland, prostate, testis, heart, lung and trachea. The canine
tumour tissues consisted of specimens of seminoma (five), fibrosarcoma (five),
osteosarcoma (four) and mammary adenocarcinoma (four). Also included were 24
malignant lymphomas, in view of the contradictory published data on the expression
of p53 by this tumour type (Gamblin et al., 1997; Sueiro et al., 2004; Sokolowska et
al., 2005). Cylinders of 1.2 mm diameter (one for each normal organ and two to four
for each of the tumour samples) were collected from representative areas of each
specimen and transferred to paraffin wax recipient blocks (Micro-Cut Paraffin,
Polysciences Inc., Warrington, PA, USA). All specimens had previously been fixed in
4% buffered formaldehyde and paraffin wax-embedded. Before sectioning, the blocks
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were immersed in water and kept at -20 °C for 15 min. Sections (1.5 µm) were
transferred to positively charged glass slides (Erie Scientific Company).
Immunohistochemistry (IHC)
Immunohistochemistry procedures were optimized for p53 antibody usage as follows.
All antibodies were first applied according to the manufacturer's instructions. If the
recommended procedure did not elicit the expected diffuse intranuclear signal with
human and selected canine tumours and cell pellets, different antigen retrieval
methods, as well as different dilutions and incubation conditions for the primary
antibody, were tested. The slides were either microwaved in acidic (citrate buffer, pH
6.0, Dako Cytomation) or alkaline buffer (Tris/EDTA buffer, pH 9.0, Dako Cytomation)
or treated with pronase (0.05%; Dako Cytomation). The antibody dilution was
decreased to as little as 1 in 10 or until non-specific staining became dominant.
Incubation with the primary antibody was carried out either overnight at 4 °C or for 1
h at room temperature. The chromogen 3-amino-9-ethyl-carbazole (AEC) was
applied for a variable period up to a maximum of 30 min. If an antibody did not show
the expected labelling pattern with any of the described procedures, it was
considered as unsuitable for IHC on paraffin wax sections.
Optimized IHC conditions were as follows. Antigen retrieval was carried out by boiling
the slides in Tris/EDTA buffer in a conventional microwave oven at 750W for 20 min.
The sections were allowed to cool for 10 min and were then incubated with the
primary antibody for 1 h at room temperature. For both cell pellets and tissues, the
following dilutions were used: CM-1 Signet 1 in 40, CM-1 Novocastra 1 in 150,
PAb240 1 in 25, PAb122 1 in 10. Endogenous peroxidase was inactivated by
immersing the slides in peroxidase blocking solution (Dako Cytomation) for 10 min at
room temperature. For detection of the primary antibody, the Detection or EnVision
Kit (Dako Cytomation) was applied according to the manufacturer's instructions.
Finally, the reaction was “visualized” by an AEC chromogen (Dako Cytomation). All
immunolabelling of tissues was performed on arrays and, if required for verification,
additionally on sections from the donor blocks. The slides were counterstained with
haemalum. Samples were considered positive when either at least 10% of the
neoplastic cells in a tumour or a subpopulation of cells within a normal tissue showed
distinct intranuclear labelling.
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Immunohistochemistry on formalin-fixed paraffin wax-embedded bacterial
pellets was performed as described above. Additionally, the primary antibody was
progressively diluted until the difference between bacteria expressing both GST and
p53 and those expressing GST only disappeared. The dilution steps were as follows
1 in 10, 25, 50, 100, 250, 500, 1000, 2500, 5000, 10 000, 20 000 and 40 000. The
highest dilution showing a clear-cut difference between p53-positive and -negative
bacteria was defined as the antibody titre.
Mutational Analysis of the TP53 Gene in Selected Samples
To facilitate interpretation of the immunohistochemical findings, a confirmatory
mutational analysis of exons 5 to 10 of the TP53 gene was performed with DNA
extracts from canine tumour samples showing positive immunohistochemical results
for p53. These samples included lymphomas 1 to 5 and the canine mammary
carcinoma indicated in Table 2. Osteosarcoma samples 1 and 2 were excluded
because of their small size.
DNA extraction from paraffin wax blocks. DNA from the tumour samples was
retrieved after trimming the original block from normal tissue to yield only tumour
tissue. Three 30-µm sections were cut and collected in an Eppendorff tube. DNA
extraction was performed with the DNeasy Blood and Tissue Extraction Kit (Quiagen
GmBH, Hilden, Germany) according to the manufacturer's instructions. Lysis was
carried out overnight at 55 °C in a shaker. The end product was eluted in 200 µl of
AE buffer (provided with the Kit).
PCR amplification of p53 exons 5 to 10. A 5-µl volume of elution product was used to
amplify each exon in a separate reaction, with Taq Gold Polymerase (Invitrogen) and
the following stated primers. Exon 5: (fwd) 5'-cgacccctctacttctcacc-3', (rev.) 5'-
agccttgtcccatctgtagc-3'. Exon 6: (fwd) 5'-agatgggacaaggctgctc-3', (rev.) 5'-
ctcccagagacccctcagat-3'. Exon 7: (fwd) 5'-tgggaaagactgaggctgat-3', (rev.) 5'-
cagtaaggaagtggccagga-3'. Exon 8: (fwd) 5'-atgagggtggctaggagtca-3', (rev.) 5'-
cctcctcttgtcttgcttgc-3'. Exon 9: (fwd) 5'-acagagggtgcaattctgct-3', (rev.) 5'-
ctagcctcacatgtgctcca-3'. Exon 10: (fwd) 5'-gtggcttccccctcttattc-3', (rev.) 5'-
gaatcctgtggctttccaac-3'. Cycling conditions were 95 °C for 10 min followed by 38
cycles of denaturing for 50 sec at 94 °C, annealing for 50 sec at a temperature
adjusted for each primer pair, and polymerization for 1 min at 72 °C. The final
extension step was 10 min at 72 °C. The PCR products yielded sizes between 207
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and 293 base pairs. They were purified with the High Pure PCR Product Purification
Kit (Roche), according to the manufacturer's instructions, and sent to a commercial
company (Microsynth AG, Balgach, Switzerland) for sequencing (cycle sequencing)
with the forward primer. The chromatograms provided by the company were
analysed manually, the sequences obtained were searched for mutations by aligning
with the dog genome sequence. For this purpose the BLAST tool available at the
National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) was
used. In the case of single unclear sequences or of a mutation, PCR and sequencing
were repeated.
Results
Testing Cross-reactivity of Antibodies with Recombinant Canine p53
The following five commercially available antibodies, raised against human p53 for
use in IHC, were selected: DO-12, DO-13, PAb122, PAb240 (all monoclonal) and
CM-1 (polyclonal). Criteria for selection were a high degree of sequence homology of
the immunogen peptide with the corresponding canine epitopes, or previously
reported use (Table 1) or both. Cross-reactivity of the antibodies with recombinant
canine p53 was then determined. All antibodies specifically recognized a GST-p53
fusion protein in western blots of bacterial lysates by labelling a band of the expected
molecular weight (Fig. 1a). No labelling was seen in the blots of lysates from GST-
protein-expressing control bacteria. As an exception, antibody CM-1 showed two
bands with a molecular weight lower than that of the fusion protein, probably
representing cross-reaction with bacterial antigens. All lysates were initially tested for
GST expression by detecting a band of the expected molecular weight by
immunoblotting with a GST-specific antibody (data not shown). In addition, all
antibodies immunolabelled formalin-fixed, paraffin wax-embedded pellets consisting
of bacteria expressing fusion protein (Fig. 1b). The difference in signal intensity
between p53-positive and -negative pellets elicited by the monoclonal antibodies was
marked. The titres (defined as the highest antibody dilution retaining a clear-cut
difference in labelling between positive and negative pellets) were 1 in 20 000 for
PAb240, 1 in 2500 for PAb122, and 1 in 250 for DO-12 and DO-13. In contrast, with
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polyclonal antibody CM-1 the difference in labelling between positive and negative
pellets was weak and difficult to reproduce, due to a variable degree of concomitant
staining of p53-negative pellets. An additional monoclonal antibody (clone DO-7)
failed to immunolabel either positive or negative bacterial pellets (data not shown)
and was therefore not further used in this study.
Fig. 1a, b. Testing of human-to-canine cross-reactivity of five p53 antibodies.
(a) Western blot analysis of E. coli lysates expressing either GST-tagged canine p53 (+) or
GST alone (-). All antibodies label a band of the expected molecular weight for the fusion
protein. (b) Immunohistochemistry of formalin-fixed and paraffin wax-embedded bacterial
pellets expressing either GST-tagged canine p53 (+) or GST alone (-). Monoclonal antibodies
clearly label p53-expressing bacteria; polyclonal antibody CM-1 less clearly discriminates
between p53-expressing and tag-only-expressing bacteria.
In-vitro Apoptosis Model with Cultured Canine Keratinocytes
An in-vitro model was developed to determine whether the selected antibodies were
suitable for the immunohistochemical detection of endogenous p53 in normal canine
tissue. Canine keratinocytes were irradiated with UVB to induce apoptosis, which
under such circumstances is mediated mainly by stabilization of p53 (Smith and
Fornace, 1997). The resulting increase of total p53 protein renders it detectable by
IHC, while protein concentrations are below detection level in the majority of
untreated cells.
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Fig. 2a-d. UVB-induced apoptosis in canine keratinocytes. (a) Giemsa staining (from
left to right: untreated control and 6, 12, 18 and 24 h after irradiation), showing increasing
monolayer disruption and apoptosis. Bars, 50 µm; the 6th image (far right) shows detail of
apoptotic cells (arrow). Bar, 10 µm. (b) Flow cytometry analysis (untreated and treated cells
24 h after irradiation), showing significant increase in Annexin V-positive and ethidium
bromide (EtBr)-negative portion in treated cells. (c) Immunohistochemistry for active
caspase-3 (untreated and treated cells 24 h after irradiation); treated, apoptotic cells are
strongly labelled, whereas healthy cells are negative. Bars, 10 µm. (d) Immunohistochemistry
for p53 (clone PAb240, untreated and treated cells 6 h after irradiation); the signal is
restricted to the nucleus of treated cells and is homogeneously spread over the whole
nuclear section area. Labelled cells are distributed in patches. Bars, 20 µm.
Successful induction of apoptosis was demonstrated morphologically in
Giemsa-stained monolayers, by Annexin V detection in flow cytometric analysis and
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by the immunohistochemical detection of cleaved caspase-3. As determined by light
microscopy of Giemsa-stained monolayers (Fig. 2a), 6 h after irradiation no signs of
apoptosis were observable. However, 12 h after UV irradiation the monolayer was
interspersed with apoptotic bodies as well as cells showing fragmented nuclei and
intense membrane blebbing. As a result, occasional gaps appeared between the
cells. Six hours later the monolayer was disrupted and large numbers of apoptotic
cells were visible. Twenty-four hours after irradiation, numerous apoptotic cells were
still present, interspersed with small patches of unaffected cells. Annexin V detection
in flow cytometric analysis confirmed the apoptotic nature of the cell death observed.
Twenty-four hours after treatment about 30% of the gated cells showed positive
staining for Annexin V while being negative for ethidium bromide. In contrast, only
5% of gated untreated cells were apoptotic (Fig. 2b). Immunolabelling of formalin-
fixed and paraffin wax-embedded irradiated cell pellets with an antibody specific for
active caspase-3 clearly demonstrated cells with apoptotic morphology and
occasional cells with unaltered appearance (Fig. 2c). In cells showing early apoptotic
changes, the signal was restricted to the cytoplasm. However, with progressing
apoptosis and disintegration of the nucleus, the cells appeared as homogeneously
labelled, round bodies with occasional dark chromatin clumps. A small number of
UV-irradiated cells with apoptotic morphology, as well as the untreated cells, were
completely devoid of active caspase-3 staining.
Of the five anti-p53 antibodies tested, PAb122, PAb240 and CM-1 (one batch
each from two different vendors) showed a labelling pattern compatible with p53
stabilization in irradiated, paraffin wax-embedded cells starting 6 h after treatment
and still visible in non-apoptotic cells 24 h after treatment (Fig. 2d and Table 2). The
signal was restricted to the nucleus and was homogeneously spread over the whole
nuclear area. Positive cells were distributed in patches, probably reflecting varying
degrees of p53 stabilization due to differences in cell cycle stage in individual cells.
The untreated control showed a few isolated, mainly weakly labelled, cells scattered
throughout the section. In contrast, no specific signal was detected with antibodies
DO-12 and DO-13. It was noteworthy that two additional batches of polyclonal
antibody CM-1 from the same vendors elicited discrepant results. One antibody
produced no labelling, while the second showed a slight increase in the number of
positive nuclei with a labelling pattern differing from that of all other antibodies in two
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consecutive experiments. In these cells, the signal had a granular appearance and
spared some areas of the nucleus, especially the nucleoli.
Table 2: Overview of p53 antibody reactivity
In-vitro Tumour tissues  with positive reaction* Normal
irradiated Human   Canine canine
canine lymphomas osteosarcomas mammary tissues
Antibody   cells     1 2 3 4 5   1 2   carcinoma    
DO-12 - + - - - - - - - - -
DO-13 - + - n.d. n.d. n.d. n.d. - - - n.d.
PAb122 + + - - - - + + + - -
PAb240 + + - - - - + + + - -
CM-1† - + + + + + - - - + +
CM-1‡ + + - - - - + + + - -
CM-1§ +/- + + + + + - - - + +
CM-1¶  +  +  - - - - +  + +  -  -
* Only positive cases out of 24 lymphomas, 4 osteosarcomas, 4 mammary carcinomas, 5 fibrosarcomas and 5 seminomas are
included. Positive lymphomas and positive osteosarcomas were numbered separately
+, Positive reaction (irradiated cells: significant increase in number of positive cells compared to negative control cells; tumours:
>10% positive cells; normal canine tissues: isolated cells labelled).
+/-, Slightly increased number of positive cells but atypical intranuclear labelling pattern. -, Negative reaction.
† Novocastra, Lot No. 300507; ‡ Novocastra, Lot No. 300509; §Signet, Lot No. 05DC00654; ¶ Signet, Lot No. 05LC02510.
n.d., Not done.
IHC of Formalin-fixed, Paraffin Wax-embedded Tissues
The next step was to explore whether cross-reacting antibodies as determined above
were suitable for use on formalin-fixed, paraffin wax-embedded, canine normal and
neoplastic tissues. The samples, which were included in tissue arrays, consisted of
human tissues with known p53 status, a panel of non-neoplastic tissues from three
different dogs, and a panel of different canine tumours. All antibodies labelled the
human controls as expected but did not label canine normal tissues with the few
exceptions indicated below (Fig. 3b). Clones DO-12 and DO-13 produced only non-
specific cytoplasmic labelling in the absence of a nuclear signal in canine tumours.
Antibodies PAb122, PAb240, and CM-1 (two batches purchased from two different
vendors) all labelled two out of three osteosarcomas (Fig. 3c)(all cores of the fourth
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osteosarcoma yielding only necrotic tissue and therefore being excluded from the
evaluation), one of 24 malignant lymphomas (Fig.3a), and none of four mammary
adenocarcinomas, five fibrosarcomas and five seminomas (Table 2). In all positive
tumours over 50% of the cells were positive. In general, PAb122 generated a weaker
signal and smaller numbers of positive cells than did the other antibodies (Fig. 3c).
No significant unspecific intranuclear labelling was detected in the normal canine
control tissues with any of the three monoclonal antibodies. Occasionally, however,
weak intracytoplasmic background staining was present with the polyclonal CM-1
antibodies.
The two additional batches of polyclonal antibody CM-1 yielded different results,
which are described and commented on in detail below. Both batches elicited an
intranuclear signal in a different subset of the canine tumours, including four of 24
malignant lymphomas (Fig. 3a) and one of four mammary adenocarcinomas (Table
2). All other neoplastic tissues were clearly negative; lymphoma case 5 showed faint
intranuclear labelling, which was considered negative. Notably, the antibodies
labelled the human positive control tissues, but the results with cultured canine
positive control cells were not satisfactory, as indicated above. In addition, these
antibodies also produced intranuclear labelling of cells in a lymph node with follicular
hyperplasia included in the normal canine tissue panel (Fig. 3b). Labelled cells were
located within both the germinal centre and the sinus regions. They included spindle
cells with elongated nuclei and macrophages, thus appearing to belong to different
lineages. All other normal canine tissues exhibited no significant labelling with these
antibodies. In lymphomas 1 and 2, and in one mammary adenocarcinoma, labelled
cells were considered neoplastic on the basis of their morphology. In lymphomas 3
and 4, additional cell types were labelled, including cells with elongated nuclei and
macrophages. To exclude an artefact associated with the tissue array technique,
sections from the original tissue blocks of lymphomas 1 to 5 and the positive
mammary adenocarcinoma were labelled. The results accorded with the findings
described above. It became evident that positive cells in lymphomas 3 and 4 were
mainly restricted to peripheral areas of the tumour tissues and to a considerable
extent consisted of non-neoplastic cells. Positive tumour cells were distributed in
clusters in lymphoma 2 and evenly in lymphoma 1 and in the positive mammary
adenocarcinoma. Finally, the results with all CM-1 antibody batches shown in Table 2
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were basically confirmed when citrate buffer was used instead of Tris/EDTA for
antigen retrieval, although the signal was less intense (data not shown).
Fig. 3a-c. Immunohistochemistry (p53) of canine tissues. (a) Lymphoma no. 1 (CM-1
Signet Lot No. 05DC00654 [top]) and lymphoma no. 5 (CM-1 Signet Lot No. 05LC02510
[bottom]); intense intranuclear labelling of cells with morphology of neoplastic lymphocytes.
(b) Lymph node with follicular hyperplasia (CM-1 Signet Lot No. 05DC00654 [top], and CM-1
Signet Lot No. 05LC02510 [bottom]); non-specific intranuclear reaction with one batch of
polyclonal antibody CM-1. (c) Osteosarcoma no. 1 (PAb240 [top] and PAb122 [bottom]);
stronger labelling with PAb240 than with PAb122.
Mutational Analysis of the TP53 Gene in Selected Samples
DNA of sufficiently good quality for PCR amplification was retrieved from tumour
tissues in lymphoma cases 1 to 5 but not from the mammary carcinoma. All
sequences of all exons examined were wild type except for exon 8 of lymphoma 5,
which displayed a mutation (A instead of G) at base 868 of the coding sequence
(starting from the ATG), resulting in a single amino-acid substitution (R instead of G)
at codon 290.
Discussion
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A system was devised for selecting p53-specific antibodies for IHC on canine tissues.
First, human-to-canine antibody cross-reactivity was tested in respect of recombinant
canine p53 protein. Western blot analysis and IHC on embedded bacteria yielded
similar results. However, the latter method was simpler, faster, and more closely
related to the final application, and worked well with monoclonal antibodies. This
procedure revealed that clone DO-7 did not cross-react with canine p53. In a
previous study this antibody failed to label putative p53-positive canine tissues
(Albaric et al., 2001), and data derived from the present study suggest that the
targeted epitope is missing in the canine molecule. All remaining monoclonal
antibodies in the present study showed specific labelling of p53-expressing bacteria
up to the dilution defined as the titre. Moreover, the titre may predict to some extent
whether an antibody is suitable for tissue IHC, since antibodies with a low titre
worked less well, if at all, than those with a higher titre. In contrast, polyclonal
antibody CM-1 was less suitable for use with embedded bacteria. This finding may
be attributable to the fact that this antibody had not been preabsorbed, and probably
contained moieties directed against bacterial antigens, as was suggested by
unspecific bands in western blots of GST-only-expressing bacterial lysates.
Nevertheless, antibody CM-1 specifically labelled recombinant p53 in western blots,
indicating that it indeed recognized canine p53. Western blotting may therefore be
better than IHC of embedded bacteria for testing polyclonal antibodies for
interspecies cross-reactivity. In conclusion, this part of the study indicated that most
commercially available antibodies against p53 can be expected to cross-react to
some extent with canine p53. Additional fusion proteins of p53 isoforms or other
family members would improve this system. In general, a selection procedure based
on recombinant protein, as described, has the advantage of unequivocally
determining cross-reactivity; this may be of particular importance when specific tissue
controls are not available.
The second step addressed the question of whether the selected antibodies
were suitable for immunohistochemical detection of endogenous p53 in normal
canine tissues. UVB-irradiated normal canine keratinocytes were used in view of
abundant published data indicating that cell death is mainly p53-dependent in this
setting (Smith and Fornace, 1997). Apoptosis was demonstrated by three different
criteria. Only three of the five antibodies cross-reacting with canine p53 (PAb122,
PAb240 and CM-1) enabled a p53 increase to be detected by IHC in UV-irradiated
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cells. These three antibodies gave consistent results in tumour tissues, indicating the
suitability of the cell culture control system. Furthermore, the cell culture experiments
made it possible to discriminate between different batches of polyclonal antibody CM-
1, supporting the notion that the labelling differences observed with additional
batches of CM-1 may have been artefactual. This was further substantiated by the
results of the mutational analysis. Antibody PAb240 is often claimed to be specific for
mutated p53, probably due to a conformational change of the protein leading to the
exposure of the relevant epitope (Gannon et al., 1990). The data from the present
cell culture experiments indicate that PAb240 in addition labels canine wild-type p53.
This may be associated with the antigen retrieval procedure, which may cause the
protein to denature, thus exposing the specific epitope; alternatively, it may reflect
conformational differences between human and canine p53.
Thus, the cell culture system used appeared to be a reliable screening method
for antibodies against p53. Furthermore, it might prove useful for testing antibodies
against other constituents of the apoptotic pathways. In support of this, the present
data indicate that the antibody against active caspase-3 used to characterize the cell
culture model may be suitable for IHC of canine tissues, as suggested by a previous
study with uterine samples (Van Cruchten et al., 2003).
The next step in this study was to investigate whether the selected antibodies
were suitable for the immunohistochemical detection of p53 in tissues. In general, the
results from tumour tissues accorded with those from cell cultures, and the sensitivity
of the antibodies accorded with the titres determined with bacterial pellets. PAb122
appeared to be less sensitive than PAb240 and CM-1, and clones DO-12 and DO-13
appeared to be unsuitable for the immunohistochemical detection of canine p53.
Overall, a surprisingly small number of positive tissues was found in the collection of
canine tumours examined; this may have been due in part to the relatively small
number of samples, to the limited area of tumour tissue examined in the tissue
arrays, or to insufficient sensitivity of the antibodies or detection system. The results
with osteosarcomas were consistent with previous findings, in which frequent p53
alterations were reported in this tumour type (Johnson et al., 1998). In fibrosarcomas,
an intermediate proportion of positive cases may be expected, as suggested by a
study in which six positives were identified in 17 (35%) samples (Gamblin et al.,
1997). The proportion of positive mammary adenocarcinomas greatly varies between
studies (Gamblin et al., 1997; Schafer et al., 1998; Rungsipipat et al., 1999; Inoue
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and Shiramizu, 1999; Haga et al., 2001; Wakui et al., 2001; Pena et al., 2003; Lee et
al., 2004). All five seminoma samples in the collection were negative, in contrast to
two previous investigations reporting immunohistochemical detection in 100% of
canine seminomas (Vitellozzi et al., 1998; Inoue and Wada, 2000). Different
antibodies were used in each of these two earlier studies, and in one of them a large
portion of normal spermatocytes were also labelled. However, data from human
studies suggest that such tumours frequently express wild-type p53 at concentrations
detectable by IHC (Houldsworth et al., 1998). This discrepancy warrants further
study.
Finally, the results point to a low proportion of p53-positive results in canine
lymphomas. Thus, Gamblin et al. (1997) and Sokolowska et al. (2005) reported 40%
of positives (six out of 15, and 21 out of 52 tumours, respectively), while Sueiro et al.
(2004) found no positives out of 28. In this type of neoplasm, factors such as non-
homogeneous distribution of positive cells and the relative numbers of neoplastic
versus non-neoplastic cells may play a role. In addition, the cut-off chosen to
distinguish possible mutation-positive from mutation-negative tumours (i.e., the
percentage of positive cells) may be important. Most authors in human and veterinary
studies set this parameter at 10%. However, others suggest that a cut-off of at least
20% is more appropriate (Ishida et al., 1997; Gao et al., 2000; Cruz et al., 2002; Zettl
et al., 2003). A further important determinant for the cut-off is the sensitivity of the
antibody used (Pardo et al., 2004). Antibodies such as PAb122, PAb240 or CM-1
have been shown in human studies to be less sensitive and of lesser prognostic
relevance than newer monoclonal antibodies (Baas et al., 1994; Xu et al., 1994).
Currently, most human medical studies use monoclonal antibodies directed against
the amino terminus of p53, which has been shown to contain a large portion of the
immunodominant epitopes (Schlichtholz et al., 1994; Munro et al., 2005). Even CM-1
appears to be mainly directed against such epitopes in human p53, since it was
found to recognize full-length p53 but not ∆133p53, a variant lacking the first 133 N-
terminal amino acids (Bourdon et al., 2005). Unfortunately, the N-terminus of canine
p53 is the region displaying the least homology with the human counterpart. In the
light of the present results and of the considerations above it appears that canine
specific antibodies would significantly improve the quality of p53 IHC in canine
tissues. However, this would not make mutational analysis dispensable if all
mutations were to be detected.
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In conclusion, a test system is described for the selection of specific antibodies
for use in IHC. The system consists of three steps, each of which has intrinsic
advantages, as shown by the example of canine p53. The use of recombinant canine
protein facilitates the exclusion of non-cross-reacting antibodies. Cell cultures with
controlled antigen expression are valuable in checking the antibodies
immunohistochemically in a homologous system and enabling those with low
sensitivity to be excluded. Homologous tissues with known high and low expression
status are of great help in substantiating further the suitability of the antibodies.
Positive human tissues are unsuitable as controls for IHC of canine tissues, but
appropriate positive and negative controls are indispensable, even in cases of a
protein with an "obvious" labelling pattern such as p53. Particular attention should be
paid to this point, especially when polyclonal antibodies raised against heterologous
antigens are used, since significant differences may occur between batches.
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